Atara Biotherapeutics’ off-the-shelf, allogeneic T-cell immunotherapy platform allows for the manufacturing of a T-cell library in advance of patient need. Our off-the-shelf, allogeneic T-cell immunotherapy candidates utilize Epstein-Barr Virus (EBV) T‑Cells from donors with healthy immune function, which are then selected and expanded to recognize diseased or cancer cells. These EBV T‑Cells are comprehensively-characterized and selected for each patient’s unique immune profile from an existing library and are rapidly available to ship to the site of patient care in approximately 3 days.
T‑Cells are part of the immune system and help protect the body from infections and may help fight cancer.
Allogeneic T‑Cells are donated from healthy individuals and are then expanded to recognize diseased or cancer cells using our unique technology. The potential advantages of this approach include:
Next-Generation CAR T technologies will seek to overcome therapeutic challenges in various medical areas.Next-Generation CAR T
Our 90,000 sq. ft. Atara T-cell Operations and Manufacturing (ATOM) facility located in Thousand Oaks, California has the capability to produce multiple T-cell and CAR T immunotherapies.
The HLA proteins present antigen to T‑Cells. Through their T-cell receptors (TCR), T‑Cells recognize HLA proteins and the antigens on the surface of cells. This interaction (TCR-HLA-antigen) is known as HLA restriction. Once activated the T‑Cells can specifically attack diseased or cancer cells in an HLA-restricted manner.
Atara’s robust pipeline includes multiple investigational T-cell immunotherapy product candidates developed using our innovative off-the-shelf, allogeneic T-cell technology platform
A collection of publications and presentations cover various areas of interest.